Cardium Therapeutics has established a diversified portfolio of medical products with large market potential. Armed with a capital-efficient, asset-based business strategy, the company is positioned to continue to build its portfolio with balanced risk/return opportunities in a variety of markets and is working to secure approval for marketing and sale in South Korea and the European Union.
Company CEO Christopher J. Reinhard founded the company in December 2003, backed by nearly 15 years of focus on the commercial development of cardiovascular growth factor therapeutics.
Under Reinhard’s leadership, Cardium is working to advance its ASPIRE Generx® clinical study at major medical centers in Russia. The company is also seeking clinical development and commercialization partners for Generx® in countries such as India, China and Brazil.
The Generx® product candidate is a minimally invasive DNA-based angiogenic growth factor therapy in development for the treatment of patients with advanced coronary artery disease. The product is being developed for international markets as an alternative treatment for patients who may not have access to surgical revascularization procedures such as coronary artery bypass surgery and angioplasty/stents.
Cardium’s Excellagen® is a syringe-based collagen gel designed to speed the growth of granulation tissue and to trigger the wound healing process. The product is FDA-cleared as treatment of neuropathic and diabetic foot ulcers, pressure ulcers, venous ulcers, surgical wounds, and other dermal wounds. Cardium is seeking commercialization partners for the marketing and sale of the product both domestically and internationally.
Cardium’s To Go Brands® develops, markets, and sells more than 25 products in support of a healthy lifestyle. The product line includes nutraceutical powder mixes, supplements, and chews sold through mass, food, and drug retailers.
Cardium is working to broaden and grow its To Go Brands® nutraceutical supplement brand platform and continues to review acquisitions of other companies and businesses to identify additional product opportunities and technologies.
For more information, visit www.cardiumthx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
